SCHEMBL9894897

SCHEMBL9894897

COC(=O)c1ccc(-n2cnc(-c3c(C)nnn3-c3ccccc3F)c2)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
RAB9A P51151 2/20 0.43
KMT2A Q03164 4/20 0.40
MEN1 O00255 2/20 0.40
NPC1 O15118 1/20 0.39
SPR P35270 1/20 0.36
KCNN4 O15554 1/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TLR2 O60603 1/20 0.35
TLR1 Q15399 1/20 0.35
MAPK14 Q16539 1/20 0.34
IDO1 P14902 1/20 0.34
TDO2 P48775 1/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9895332 0.90 SPR (0.38) SPRALDH1A1MAPK14LMNA
SCHEMBL9895495 0.89 SPR (0.37) SPRKCNN4MAPK14
SCHEMBL9896773 0.89 GABRA5 (0.37) KMT2AMEN1SPR
SCHEMBL9895440 0.88 IDO1 (0.41) KMT2AMEN1KCNN4KDM4EALDH1A1
SCHEMBL9894926 0.85 RIPK2 (0.44) MAPK14CYP2C9RIPK2
SCHEMBL9894949 0.85 RAB9A (0.40) MAPTRAB9AKMT2ANPC1KDM4E
SCHEMBL9895387 0.84 CNR2 (0.40) RAB9ANPC1SPRKCNN4
SCHEMBL9894508 0.83 CYP2C9 (0.44) MAPK14CYP2C9
SCHEMBL21416227 0.83 ALDH1A1 (0.45) RAB9AKDM4EALDH1A1SMN1; SMN2LMNA
SCHEMBL9894812 0.83 MAPK8 (0.40) RAB9ANPC1KDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2649064-B1 NOVEL TRIAZOLE COMPOUNDS III HOFFMANN LA ROCHE (CH) 2019-10-02 EP disclosed
EP-2649064-A1 NOVEL TRIAZOLE COMPOUNDS III F. Hoffmann-La Roche AG (CH) 2013-10-16 EP disclosed
US-8466181-B2 1,2,3-triazole-imidazole compounds HOFFMANN-LA ROCHE INC. (US) 2013-06-18 US disclosed
US-20120149675-A1 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS HOFFMANN-LA ROCHE INC. 2012-06-14 US disclosed
WO-2012076590-A1 NOVEL TRIAZOLE COMPOUNDS III F. HOFFMANN-LA ROCHE AG (CH) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149675-A1 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS GABRA5, GABRA1, GABRB1 MAPT 1958/4885RAB9A 1128/4885KMT2A 3752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.